Anti-HIV-1 activity of elafin is more potent than its precursor's, trappin-2, in genital epithelial cells

Journal of Virology

Volumn 86, Issue 8, 2012, Pages 4599-4610

  Drannik, Anna G ^a   Nag, Kakon ^a   Yao, Xiao Dan ^a   Henrick, Bethany M ^a   Jain, Sumiti ^a   Blake Ball, T ^b,c   Plummer, Francis A ^b,c   Wachihi, Charles ^d   Kimani, Joshua ^d   Rosenthal, Kenneth L ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; CHEMOKINE RECEPTOR CXCR4; ELAFIN; LEUKOCYTE ELASTASE; PROTEIN PRECURSOR; SMALL INTERFERING RNA; SYNDECAN 1; TRAPPIN 2; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL SURFACE; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCYTOSIS; VIRUS ATTACHMENT; VIRUS INHIBITION; VIRUS SHEDDING;

ANTI-HIV AGENTS; ANTIGENS, CD4; CELL LINE; ELAFIN; EPITHELIAL CELLS; FEMALE; GENE SILENCING; GENITALIA, FEMALE; HIV-1; HUMANS; IMMUNITY, MUCOSAL; LEUKOCYTE ELASTASE; RECEPTORS, CXCR5; RNA, SMALL INTERFERING; TRANSCYTOSIS; VIRUS ATTACHMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84861364539     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06561-11     Document Type: Article

References (86)

1. + memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infection. J. Virol. 82:471-486.
2. Andersen JH, Jenssen H, Sandvik K, Gutteberg TJ. 2004. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J. Med. Virol. 74:262-271.
3. Bachan S, Fantini J, Joshi A, Garg H, Mootoo DR. 2011. Synthesis, gp120 binding and anti-HIV activity of fatty acid esters of 1,1-linked disaccharides. Bioorg. Med. Chem. 19:4803-4811.
4. Baranger K, Zani ML, Chandenier J, Dallet-Choisy S, Moreau T. 2008. The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function. FEBS J. 275:2008-2020.
5. Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Soderlund J. 2007. The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr. HIV Res. 5:410-415.
6. Bingle CD, Vyakarnam A. 2008. Novel innate immune functions of the whey acidic protein family. Trends Immunol. 29:444-453.
7. Bobardt MD, Chatterji U, Schaffer L, de Witte L, Gallay PA. 2010. Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrob. Agents Chemother. 54:2753-2766.
8. Bobardt MD, et al. 2007. Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J. Virol. 81:395-405.
9. Bobardt MD, et al. 2003. Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 18:27-39.
10. Butler MW, et al. 2006. Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J. Biol. Chem. 281:34730-34735.
11. Chang TL, Vargas J, Jr, DelPortillo A, Klotman ME. 2005. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J. Clin. Invest. 115:765-773.
12. Cowan B, et al. 1996. Elafin, a serine elastase inhibitor, attenuates postcardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits after heterotopic cardiac transplantation. J. Clin. Invest. 97: 2452-2468.
13. Drannik AG, Henrick BM, Rosenthal KL. 2011. War and peace between WAP and HIV: role of SLPI, trappin-2, elafin and ps20 in susceptibility to HIV infection. Biochem. Soc. Trans. 39:1427-1432.
14. Fahey JV, et al. 2011. New approaches to making the microenvironment of the female reproductive tract hostile to HIV. Am. J. Reprod. Immunol. 65:334-343.
15. Fahey JV, Schaefer TM, Channon JY, Wira CR. 2005. Secretion of cytokines and chemokines by polarized human epithelial cells from the female reproductive tract. Hum. Reprod. 20:1439-1446.
16. Farquhar C, et al. 2002. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J. Infect. Dis. 186:1173-1176.
17. Fowke KR, et al. 1996. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 348:1347-1351.
18. Garg H, et al. 2008. Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry. Antiviral Res. 80:54-61.
19. Ghosh M, et al. 2010. Anti-HIV activity in cervical-vaginal secretions from HIV-positive and-negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One 5:e11366.
20. Ghosh M, et al. 2010. Trappin-2/elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology 129:207-219.
21. Guyot N, Zani ML, Berger P, Dallet-Choisy S, Moreau T. 2005. Proteolytic susceptibility of the serine protease inhibitor trappin-2 (preelafin): evidence for tryptase-mediated generation of elafin. Biol. Chem. 386:391-399.
22. Guyot N, Zani ML, Maurel MC, Dallet-Choisy S, Moreau T. 2005. Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Biochemistry 44:15610-15618.
23. Hagiwara K, Kikuchi T, Endo Y, Huqun et al. 2003. Mouse SWAM1 and SWAM2 are antibacterial proteins composed of a single whey acidic protein motif. J. Immunol. 170:1973-1979.
24. Harouse JM, et al. 1991. Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science 253:320-323.
25. Harouse JM, Collman RG, Gonzalez-Scarano F. 1995. Human immunodeficiency virus type 1 infection of SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3= sulfogalactosyl ceramide-positive cell line. J. Virol. 69:7383-7390.
26. Hazrati E, et al. 2006. Human alpha-and beta-defensins block multiple steps in herpes simplex virus infection. J. Immunol. 177:8658-8666.
27. Henriksen PA, et al. 2004. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J. Immunol. 172:4535-4544.
28. Hickey DK, Patel MV, Fahey JV, Wira CR. 2011. Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J. Reprod. Immunol. 88:185-194.
29. Hocini H, et al. 2000. Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers. Clin. Diagn. Lab. Immunol. 7:515-518.
30. Iqbal SM, et al. 2009. Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 23:1669-1677.
31. Jain S, Rosenthal KL. 2011. The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis. Mucosal Immunol. 4:539-553.
32. Kaul R, et al. 2000. HIV-1-specific mucosal CD8+lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 164: 1602-1611.
33. Kaul R, et al. 2001. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J. Clin. Invest. 107:341-349.
34. Kaul R, et al. 1999. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 13:23-29.
35. King AE, Critchley HO, Kelly RW. 2003. Innate immune defences in the human endometrium. Reprod. Biol. Endocrinol. 1:116.
36. King AE, Critchley HO, Sallenave JM, Kelly RW. 2003. Elafin in human endometrium: an antiprotease and antimicrobial molecule expressed during menstruation. J. Clin. Endocrinol. Metab. 88:4426-4431.
37. King AE, et al. 2006. Expression of natural antimicrobials by human placenta and fetal membranes. Placenta 28:161-169.
38. Lorin C, et al. 2005. The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. Virology 334:264-275.
39. Ma G, et al. 2004. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J. Exp. Med. 200:1337-1346.
40. Mann DM, Romm E, Migliorini M. 1994. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. J. Biol. Chem. 269:23661-23667.
41. McClure CP, et al. 2005. HIV coreceptor and chemokine ligand gene expression in the male urethra and female cervix. AIDS 19:1257-1265.
42. McMichael JW, et al. 2005. Antimicrobial activity of murine lung cells against Staphylococcus aureus is increased in vitro and in vivo after elafin gene transfer. Infect. Immun. 73:3609-3617.
43. McMichael JW, Roghanian A, Jiang L, Ramage R, Sallenave JM. 2005. The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. Am. J. Respir. Cell Mol. Biol. 32:443-452.
44. McNeely TB, et al. 1997. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90:1141-1149.
45. Mihaila A, Tremblay GM. 2001. Human alveolar macrophages express elafin and secretory leukocyte protease inhibitor. Z. Naturforsch. C 56: 291-297.
46. Mondor I, Ugolini S, Sattentau QJ. 1998. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J. Virol. 72:3623-3634.
47. Montefiori DC. 2009. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485:395-405.
48. Moreau T, et al. 2008. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 90:284-295.
49. Nair DG, Fry BG, Alewood P, Kumar PP, Kini RM. 2007. Antimicrobial activity of omwaprin, a new member of the waprin family of snake venom proteins. Biochem. J. 402:93-104.
50. Nara K, et al. 1994. Elastase inhibitor elafin is a new type of proteinase inhibitor which has transglutaminase-mediated anchoring sequence termed "cementoin." J. Biochem. 115:441-448.
51. Nazli A, et al. 2010. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 6:e1000852.
52. Nazli A, et al. 2009. Differential induction of innate anti-viral responses by TLR ligands against herpes simplex virus, type 2, infection in primary genital epithelium of women. Antiviral Res. 81:103-112.
53. Pfundt R, et al. 1996. Constitutive and inducible expression of SKALP/ elafin provides anti-elastase defense in human epithelia. J. Clin. Invest. 98:1389-1399.
54. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72: 2855-2864.
55. Pol A, Pfundt R, Zeeuwen P, Molhuizen H, Schalkwijk J. 2003. Transcriptional regulation of the elafin gene in human keratinocytes. J. Invest. Dermatol. 120:301-307.
56. Py B, et al. 2009. The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane. PLoS One 4:e5006.
57. Roghanian A, et al. 2006. The antimicrobial/elastase inhibitor elafin regulates lung dendritic cells and adaptive immunity. Am. J. Respir. Cell Mol. Biol. 34:634-642.
58. Saidi H, et al. 2006. Differential modulation of human lactoferrin activity against both R5 and X4-HIV-1 adsorption on epithelial cells and dendritic cells by natural antibodies. J. Immunol. 177:5540-5549.
59. Saidi H, Magri G, Nasreddine N, Requena M, Belec L. 2007. R5-and X4-HIV-1 use differentially the endometrial epithelial cells HEC-1A to ensure their own spread: implication for mechanisms of sexual transmission. Virology 358:55-68.
60. Sallenave JM. 2010. Secretory leukocyte protease inhibitor and elafin/ trappin-2: versatile mucosal antimicrobials and regulators of immunity. Am. J. Respir. Cell Mol. Biol. 42:635-643.
61. Sallenave JM, Shulmann J, Crossley J, Jordana M, Gauldie J. 1994. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am. J. Respir. Cell Mol. Biol. 11:733-741.
62. Saphire AC, Bobardt MD, Zhang Z, David G, Gallay PA. 2001. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J. Virol. 75:9187-9200.
63. Schaefer TM, Fahey JV, Wright JA, Wira CR. 2005. Innate immunity in the human female reproductive tract: antiviral response of uterine epithelial cells to the TLR3 agonist poly(I:C). J. Immunol. 174:992-1002.
64. Schalkwijk J, Chang A, Janssen P, De Jongh GJ, Mier PD. 1990. Skinderived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis. Br. J. Dermatol. 122:631-641.
65. Schalkwijk J, Wiedow O, Hirose S. 1999. The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem. J. 340:569-577.
66. Seganti L, et al. 2004. Antiviral activity of lactoferrin towards naked viruses. Biometals 17:295-299.
67. Shafti-Keramat S, et al. 2003. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 77:13125-13135.
68. Shust GF, et al. 2010. Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am. J. Reprod. Immunol. 63: 110-119.
69. Simpson AJ, Cunningham GA, Porteous DJ, Haslett C, Sallenave JM. 2001. Regulation of adenovirus-mediated elafin transgene expression by bacterial lipopolysaccharide. Hum. Gene Ther. 12:1395-1406.
70. Simpson AJ, Maxwell AI, Govan JR, Haslett C, Sallenave JM. 1999. Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens. FEBS Lett. 452:309-313.
71. Simpson AJ, et al. 2001. Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection. J. Immunol. 167:1778-1786.
72. Steinstraesser L, et al. 2005. Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology 2:2.
73. Tsunemi M, Matsuura Y, Sakakibara S, Katsube Y. 1996. Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution. Biochemistry 35:11570-11576.
74. Turville SG, et al. 2002. Diversity of receptors binding HIV on dendritic cell subsets. Nat. Immunol. 3:975-983.
75. UNAIDS. 2009. UNAIDS global report 2009. UNAIDS, Geneva, Switzerland.
76. van Wetering S, et al. 2000. Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. Am. J. Physiol. Lung Cell Mol. Physiol. 278:L51-L58.
77. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM. 2005. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J. Immunol. 175:7560-7567.
78. Wehkamp J, Schmid M, Stange EF. 2007. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr. Opin. Gastroenterol. 23:370-378.
79. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
80. Wilkinson TS, et al. 2009. Trappin-2 promotes early clearance of Pseudomonas aeruginosa through CD14-dependent macrophage activation and neutrophil recruitment. Am. J. Pathol. 174:1338-1346.
81. Wira CR, Fahey JV. 2008. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 22:1909-1917.
82. Wira CR, et al. 2011. Epithelial cell secretions from the human female reproductive tract inhibit sexually transmitted pathogens and Candida albicans but not Lactobacillus. Mucosal Immunol. 4:335-342.
83. Wira CR, Grant-Tschudy KS, Crane-Godreau MA. 2005. Epithelial cells in the female reproductive tract: a central role as sentinels of immune protection. Am. J. Reprod. Immunol. 53:65-76.
84. Wu Z, Chen Z, Phillips DM. 2003. Human genital epithelial cells capture cell-free human immunodeficiency virus type 1 and transmit the virus to CD4+cells: implications for mechanisms of sexual transmission. J. Infect. Dis. 188:1473-1482.
85. Yahi N, Baghdiguian S, Moreau H, Fantini J. 1992. Galactosyl ceramide (or a closely related molecule) is the receptor for human immunodeficiency virus type 1 on human colon epithelial HT29 cells. J. Virol. 66: 4848-4854.
86. Yenugu S, et al. 2004. Antimicrobial activity of human EPPIN, an androgen-regulated, sperm-bound protein with a whey acidic protein motif. Biol. Reprod. 71:1484-1490.